To evaluate the effect of tablet pregabalin and tablet duloxetine with tablet pregabalin and tablet nortriptyline in neuropathic pain after herpes and changes in HLA-A33 and HLA-B44 GENES.

A RANDOMIZED COMPARATIVE STUDY EVALUATING THE EFFICACY OF PREGABALIN AND DULOXETINE Versus PREGABALIN AND NORTRIPTYLINE AND THE MODULATION OF mRNA EXPRESSION OF HLA-A33 AND HLA-B44 GENES IN PATIENTS OF POST-HERPETIC NEURALGIA

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/024235

Enrollment

Registered

2020-03-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Nil: Nil Control Intervention1: Tablet Pregabalin and Tablet Duloxetine in comparison with tablet Pregabalin and tablet Nortriptyline in patients of post herpetic neuralgia.: Tablet Pr

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients should have a diagnosis of PHN with evident hyperalgesia and allodynia. 2. Patients of PHN should have pain for at least 12 weeks after the healing of rash. 3.Pain intensity >= 4 on 10 of NRS-pain scale

Exclusion criteria

Exclusion criteria: 1.Patients with history of neurological intervention for PHN. 2.Evidence of other sources of chronic or acute pain that may confound the diagnosis 3. Known history of intake Pregabalin or Duloxetine for PHN in past 4 weeks. 4. Patients with past h/o MI, DM, pancreatitis and vasculitis. 5. Patients with evidence of renal impairment/history of alcohol consumption and smoking. 6.Patients with psychiatric or substance abuse disorder.

Design outcomes

Primary

Measure	Time frame
Proportion of patients achieving NRS-pain score of 4/10 at the end of 12th week in both the groups. 2. The neuropathic component of pain using NPSI score in both the groups.Timepoint: At baseline and at the end of 1st week, 2nd week, 4th week, 8th week and 12th week.	—

Secondary

Measure	Time frame
1. NRS-sleep score in the two groups at various designated intervals. 2. PDQ score in both the groups at various designated intervals. 3. The quality of life (QoL) using SF-12 score in the two groups at various designated intervals. 4. Modulation in mRNA expressions of HLA-A33 and HLA-B44 genes at baseline and after 12 weeks of treatment.Timepoint: At baseline and at the end of 1st week, 2nd week, 4th week, 8th week and 12th week.	—

Measure

Time frame

1. NRS-sleep score in the two groups at various designated intervals. 2. PDQ score in both the groups at various designated intervals. 3. The quality of life (QoL) using SF-12 score in the two groups at various designated intervals. 4. Modulation in mRNA expressions of HLA-A33 and HLA-B44 genes at baseline and after 12 weeks of treatment.Timepoint: At baseline and at the end of 1st week, 2nd week, 4th week, 8th week and 12th week.

—

Countries

India

Contacts

Public ContactDr Prerna Vasudev

University College Of Medical Sciences and GTB Hospital

profashoksaxena2@gmail.com9810431367

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026